Somerset's Eldepryl for Parkinson's will be copromoted by Cocensys.
Executive Summary
SOMERSET's ELDEPRYL WILL BE COPROMOTED BY CONCENSYS and its 70-person CNS field force in place of Sandoz after the end of the first quarter. Somerset Pharmaceuticals, the joint venture of Mylan Labs and Watson Pharmaceuticals, has signed on Cocensys to copromote selegiline for the treatment of Parkinson's disease in the U.S. Sandoz has been marketing the drug since Oct. 1, 1990. The companies agreed in 1995 to terminate that deal after March 31.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth